These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 34546785)
1. Landscape Analysis of Breast Cancer and Acute Myeloid Leukemia Trials Using the My Cancer Genome Clinical Trial Data Model. Jain NM; Holt M; Micheel C; Levy M JCO Clin Cancer Inform; 2021 Sep; 5():975-984. PubMed ID: 34546785 [TBL] [Abstract][Full Text] [Related]
2. The My Cancer Genome clinical trial data model and trial curation workflow. Jain N; Mittendorf KF; Holt M; Lenoue-Newton M; Maurer I; Miller C; Stachowiak M; Botyrius M; Cole J; Micheel C; Levy M J Am Med Inform Assoc; 2020 Jul; 27(7):1057-1066. PubMed ID: 32483629 [TBL] [Abstract][Full Text] [Related]
3. My Cancer Genome: Coevolution of Precision Oncology and a Molecular Oncology Knowledgebase. Holt ME; Mittendorf KF; LeNoue-Newton M; Jain NM; Anderson I; Lovly CM; Osterman T; Micheel C; Levy M JCO Clin Cancer Inform; 2021 Sep; 5():995-1004. PubMed ID: 34554823 [TBL] [Abstract][Full Text] [Related]
4. Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis. Parker JL; Kuzulugil SS; Pereverzev K; Mac S; Lopes G; Shah Z; Weerasinghe A; Rubinger D; Falconi A; Bener A; Caglayan B; Tangri R; Mitsakakis N Cancer Med; 2021 Mar; 10(6):1955-1963. PubMed ID: 33620160 [TBL] [Abstract][Full Text] [Related]
5. The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies. Patterson SE; Liu R; Statz CM; Durkin D; Lakshminarayana A; Mockus SM Hum Genomics; 2016 Jan; 10():4. PubMed ID: 26772741 [TBL] [Abstract][Full Text] [Related]
7. Biomarkers for personalized oncology: recent advances and future challenges. Kalia M Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140 [TBL] [Abstract][Full Text] [Related]
8. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Short NJ; Konopleva M; Kadia TM; Borthakur G; Ravandi F; DiNardo CD; Daver N Cancer Discov; 2020 Apr; 10(4):506-525. PubMed ID: 32014868 [TBL] [Abstract][Full Text] [Related]
9. The clinical impact of the molecular landscape of acute myeloid leukemia. Kayser S; Levis MJ Haematologica; 2023 Feb; 108(2):308-320. PubMed ID: 36722402 [TBL] [Abstract][Full Text] [Related]
10. [Current clinical trials using new targeted therapies for myeloid leukemia and the research trends]. Ishizawa J; Saya H Nihon Rinsho; 2009 Oct; 67(10):1932-7. PubMed ID: 19860193 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic therapies in acute myeloid leukemia: where to from here? Fennell KA; Bell CC; Dawson MA Blood; 2019 Nov; 134(22):1891-1901. PubMed ID: 31697822 [TBL] [Abstract][Full Text] [Related]
12. The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs. Mohamed L; Manjrekar S; Ng DP; Walsh A; Lopes G; Parker JL Oncologist; 2022 Oct; 27(10):849-856. PubMed ID: 35993585 [TBL] [Abstract][Full Text] [Related]
13. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Pollyea DA; Gutman JA; Gore L; Smith CA; Jordan CT Haematologica; 2014 Aug; 99(8):1277-84. PubMed ID: 25082785 [TBL] [Abstract][Full Text] [Related]
14. Future prospects of therapeutic clinical trials in acute myeloid leukemia. Khan M; Mansoor AE; Kadia TM Future Oncol; 2017 Mar; 13(6):523-535. PubMed ID: 27771959 [TBL] [Abstract][Full Text] [Related]
15. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Zeng AGX; Bansal S; Jin L; Mitchell A; Chen WC; Abbas HA; Chan-Seng-Yue M; Voisin V; van Galen P; Tierens A; Cheok M; Preudhomme C; Dombret H; Daver N; Futreal PA; Minden MD; Kennedy JA; Wang JCY; Dick JE Nat Med; 2022 Jun; 28(6):1212-1223. PubMed ID: 35618837 [TBL] [Abstract][Full Text] [Related]
16. The Evolving AML Genomic Landscape: Therapeutic Implications. Horibata S; Alyateem G; DeStefano CB; Gottesman MM Curr Cancer Drug Targets; 2020; 20(7):532-544. PubMed ID: 32329691 [TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
18. Sustained expression of nucleophosmin (NPM1) mutation at late relapse presenting as isolated myeloid sarcoma in a patient with acute myeloid leukemia. Scholl S; Lüftner J; Mügge LO; Schmidt V; Fricke HJ; Höffken K Ann Hematol; 2007 Oct; 86(10):763-5. PubMed ID: 17639390 [No Abstract] [Full Text] [Related]
19. Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine. Lam SS; He AB; Leung AY Blood Rev; 2017 Nov; 31(6):418-425. PubMed ID: 28797519 [TBL] [Abstract][Full Text] [Related]
20. Acute Myeloid Leukemia: Diagnosis and Management Based on Current Molecular Genetics Approach. Suguna E; Farhana R; Kanimozhi E; Kumar PS; Kumaramanickavel G; Kumar CS Cardiovasc Hematol Disord Drug Targets; 2018; 18(3):199-207. PubMed ID: 29766829 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]